文献速递心力衰竭与心肌病瓣膜病与结构性心脏病肺血管病与心包/心肌炎

右心室指标作为临床试验终点的综述

Right Ventricular Metrics as End Points in Clinical Trials: A Review.
PubMed 文献 · JAMA Cardiol · 2026-01-01

该综述探讨了右心室(RV)影像与血流动力学参数作为临床试验终点的现状与前景,指出其在心衰、心肌病、瓣膜病、肺高血压和先天性心脏病等领域有潜在价值,但应用不一致且可行性挑战常见。作者提出需标准化采集、验证临床有意义变化并集中数据分析,以促进更广泛应用。

要点

  • RV指标在多种心血管疾病临床试验中显示潜在价值但应用不一致。
  • 主要局限包括采集变异、数据不完整、缺乏标准化方案和验证不足。
  • 标准化采集、验证有意义变化和集中分析是重要下一步。

核心结论

  • RV特异性终点有潜力提高临床试验敏感性和机制洞察,但尚未充分整合到当前实践中。

研究设计与样本

  • 本文为综述,探讨了RV聚焦的影像和血流动力学参数作为临床试验终点的当前和新兴作用,并提出了开发、验证和更广泛实施的综合框架。

主要发现

  • 来自超声心动图、心脏磁共振、计算机断层扫描和右心导管术的RV聚焦参数在心衰、心肌病、瓣膜病、肺高血压和先天性心脏病等多种疾病领域显示评估治疗效果的潜在价值。
  • RV参数的使用不一致,可行性挑战常见,尤其是在多中心临床试验环境中。
  • 关键局限包括影像采集变异、数据捕获不完整、缺乏标准化方案以及将短期RV变化与长期临床结局关联的验证不足。
  • 人工智能等新兴工具可能提高可重复性和效率,协作和多学科努力对推进终点开发至关重要。

临床怎么用

  • 最佳终点选择需平衡临床相关性、分析有效性和操作可行性,并考虑疾病特异性病理生理和试验设计。
  • 标准化采集、验证临床有意义变化和集中数据分析是重要下一步。
  • 更广泛采用稳健的RV指标,辅以技术创新和跨部门合作,有潜力提高试验效率、加速治疗开发并最终改善患者结局。

局限性

  • RV参数在多中心临床试验中应用不一致且可行性挑战常见。
  • 影像采集变异、数据捕获不完整、缺乏标准化方案。
  • 将短期RV变化与长期临床结局关联的验证不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical trials in cardiovascular medicine aim to deliver high-quality evidence with greater efficiency, including smaller sample sizes and shorter timelines. The selection of sensitive and reliable end points is central to this goal. Right ventricular (RV) structure and function play a critical role in many cardiovascular conditions; however, RV-specific parameters remain underused and inconsistently applied in interventional clinical trials. In this article, the current and emerging role of RV-focused imaging and hemodynamic parameters as end points in clinical trials are explored and a comprehensive framework for their development, validation, and broader implementation is proposed. OBSERVATIONS: Across multiple disease domains, RV-focused parameters derived from echocardiography, cardiac magnetic resonance imaging, computed tomography, and right-sided heart catheterization demonstrate potential value in assessing the therapeutic effects of new medicines or devices across a wide range of conditions including heart failure, cardiomyopathies, valve diseases, pulmonary hypertension, and congenital heart conditions. However, their use is inconsistent, and feasibility challenges are common, particularly in multicenter clinical trial settings. Key limitations include variability in imaging acquisition, incomplete data capture, lack of standardized protocols, and insufficient validation linking short-term RV changes to long-term clinical outcomes. Emerging tools such as artificial intelligence may improve reproducibility and efficiency, while collaborative, multidisciplinary efforts are essential for advancing end-point development. CONCLUSIONS AND RELEVANCE: RV-specific end points hold substantial promise for enhancing the sensitivity and mechanistic insight of clinical trials but remain inadequately integrated into current practice. Optimal end-point selection requires balancing clinical relevance, analytical validity, and operational feasibility, with consideration of disease-specific pathophysiology and trial design. Standardization of acquisition, validation of clinically meaningful changes, and centralized data analysis are important next steps. Broader adoption of robust RV metrics supported by technological innovation and cross-sector collaboration has the potential to improve trial efficiency, accelerate therapeutic development, and ultimately enhance patient outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Surkova E, Lakatos B, Kempton H, et al. Right Ventricular Metrics as End Points in Clinical Trials: A Review. JAMA Cardiol. 2026. PMID: 42340710. doi:10.1001/jamacardio.2026.2053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。